Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NKTX
- Price
- 1.77
- Stock movement up
- +0.06 (2.65%)
- Company name
- Nkarta Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 164.78M
- Ent value
- 208.98M
- Price/Sales
- 15.63
- Price/Book
- 0.38
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -55.47%
- 3 year return
- -49.23%
- 5 year return
- -39.22%
- 10 year return
- -
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NKTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.63 |
| Price to Book | 0.38 |
| EV to Sales | 19.82 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.02M |
| EPS (TTM) | -1.50 |
| FCF per share (TTM) | -1.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.54M |
| Gross profit (TTM) | 3.77M |
| Operating income (TTM) | -128.46M |
| Net income (TTM) | -110.61M |
| EPS (TTM) | -1.50 |
| EPS (1y forward) | -1.39 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 35.80% |
| Operating margin (TTM) | -1218.52% |
| Profit margin (TTM) | -1049.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 56.96M |
| Net receivables | 0.00 |
| Total current assets | 290.15M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 532.03M |
| Accounts payable | 1.94M |
| Short/Current long term debt | 85.45M |
| Total current liabilities | 22.47M |
| Total liabilities | 101.16M |
| Shareholder's equity | 430.87M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -98.30M |
| Capital expenditures (TTM) | 10.11M |
| Free cash flow (TTM) | -108.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.67% |
| Return on Assets | -20.79% |
| Return on Invested Capital | -25.27% |
| Cash Return on Invested Capital | -24.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.25 |
| Daily high | 2.32 |
| Daily low | 2.23 |
| Daily Volume | 271K |
| All-time high | 75.62 |
| 1y analyst estimate | 12.40 |
| Beta | 0.73 |
| EPS (TTM) | -1.50 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| NKTX | S&P500 | |
| Current price drop from All-time high | -96.93% | -1.46% |
| Highest price drop | -98.27% | -56.47% |
| Date of highest drop | 2 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -78.24% | -10.99% |
| Avg time to new high | 143 days | 12 days |
| Max time to new high | 1170 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
164.78M
Marketcap category
Small-cap
Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Employees
110
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page